Ganitumab for the treatment of small-cell lung cancer.

about

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review.

P2860

Q36811784-F9BD4C6D-D0BE-46A9-9F8C-020105CDD3A3 Q47640411-00238919-92E7-4C95-9DE2-E45572CB2EC8

P2860

Ganitumab for the treatment of small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q38246143

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Ganitumab for the treatment of small-cell lung cancer.

@en

type

Item

label

Ganitumab for the treatment of small-cell lung cancer.

@en

prefLabel

Ganitumab for the treatment of small-cell lung cancer.

@en

P1476

Ganitumab for the treatment of small-cell lung cancer.

@en

P2093

Pablo Martínez

http://www.w3.org/2001/XMLSchema#string

Paula Alexandra Sales Fidalgo

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Structure and functional analysis of the IGF-II/IGF2R interaction

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.

A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.

P304

1423-1432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.951434

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Enriqueta Felip

P577

2014-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25189625

http://www.w3.org/2001/XMLSchema#string

Ganitumab for the treatment of small-cell lung cancer.

about

P2860

P2860

Ganitumab for the treatment of small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698